

SARS CoV-2 Spike Glycoprotein Blocking Peptide for STJ506290 peptide (STJ506292)

STJ506292

GENERAL INFORMATION

Product Type Biomolecules

Short SARS CoV-2 Spike Glycoprotein Blocking Peptide for STJ506290 is synthetically produced from the 1-100 sequence and is

Description suitable for use in western blot applications. **Applications** Immunodepletion/Immunocompetition

Host/Source Reactivity

PRODUCT PROPERTIES

Clonality Clone ID Concentration Conjugation Purification

Dilution Range

Formulation Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized

powder form, or in buffer of choice.

Isotype

Storage Store at-20°C for long term storage. Avoid freeze-thaw cycles.

Instruction

TARGET INFORMATION

Gene ID
Gene Symbol
Uniprot ID
Immunogen
Immunogen
Region

Specificity This blocking peptide is recommended for use in combination with SARS CoV-2 Spike Glycoprotein antibody, STJ506290

Immunogen Sequence

This product is suitable for in-vitro studies under the RESEARCH USE ONLY [RUO] licence. This product must not be used as for diagnostic or other medical purposes. St John's Laboratory Ltd, Knowledge Dock Business Centre, University Way, London, E16 2RD | Tel: 0208 223 3081